Join our daily newsletter At The Bell to receive exclusive market insights
- Medibio (MEB) has begun the second test phase of its mental health app ahead of its commercial launch in October
- The company aims to address the increased demand for online mental health services, through its app, which will be available on Android and iOS platforms
- The app will offer cognitive behavioural exercises, educational tools and goal setting features to help user develop solutions that work best for them
- Medibio is up 6.25 per cent, trading at 0.9 cents
Medibio (MEB) has begun the second test phase of its mental health app ahead of its commercial launch in October.
Medibio aims to address the increased demand for online mental health services through the development of the app, which will be available on Android and iOS platforms.
The company says the COVID pandemic exacerbated mental health conditions amongst the global population. In the U.S. alone, increased stress and anxiety has adversely impacted the mental health of an estimated 53 per cent of adults, with 71 per cent reporting that they could have used more emotional support.
Medibio’s app will identify how stress affects the user, considering their personality type and emotional characteristics.
The data collected during this test phase will then be used to further refine Medibio’s algorithms that produce a daily individual-based stress result for sleep, activity and heart rate that will contribute to an overall stress assessment.
The app will also offer cognitive behavioural exercises, educational tools and goal setting features to help user develop solutions that work best for them.
All of the recommended activities and resources are based on clinical research and validated by Medibio’s clinical research partner, the Humanitas University in Italy and Medibio’s Chief Medical Officer.
The second test phase, that began on April 12, assesses the app’s connectivity with wearable devices, and the efficacy of undertaking the app’s psychometric stress assessment on mobile and wearable devices.
The app will first launch in the U.S., before later being available for download in multiple regions globally through the App Store and the Google Play Store.
Medibio is up 6.25 per cent, trading at 0.9 cents at 3:50 pm AEST.
